AXSOME THERAPEUTICS Reaches New Heights with Stock Surging to 52-Week High of $98.61
☀️Trending News AXSOME THERAPEUTICS ($NASDAQ:AXSM) is a biopharmaceutical company focused on developing innovative therapies for the treatment of central nervous [...]
Mizuho Securities Reaffirms Outperform Rating for Axsome Therapeutics, Sets $106 Price Target
☀️Trending News Axsome Therapeutics ($NASDAQ:AXSM) is a biopharmaceutical company that focuses on developing novel therapies for the treatment of central [...]
TD Cowen Remains Bullish on Axsome Therapeutics with Buy Rating and $120 Price Target Amid Promising Pipeline Progress
☀️Trending News Axsome Therapeutics ($NASDAQ:AXSM) is a pharmaceutical company that focuses on developing innovative treatments for central nervous system (CNS) [...]
Axsome Therapeutics Reports Expected Q4 Revenue of $71M
🌥️Trending News Axsome Therapeutics ($NASDAQ:AXSM), a biopharmaceutical company that focuses on the development and commercialization of therapies for the management [...]
AXSOME THERAPEUTICS Insider Activity: What Investors Need to Know
🌥️Trending News Investors in Axsome Therapeutics ($NASDAQ:AXSM) Inc AXSM need to know the latest insider activity in order to make [...]
Should Investors Sell Axsome Therapeutics Inc (AXSM) After Insider Sale Alert?
☀️Trending News Investors of Axsome Therapeutics ($NASDAQ:AXSM) Inc (AXSM) may be wondering if they should sell their shares in the [...]
Axsome Therapeutics Sees Positive Q3, Showing Promise as Launch Success Story
☀️Trending News Axsome Therapeutics ($NASDAQ:AXSM) has experienced tremendous success in its launch and is quickly becoming a success story. Axsome [...]
AXSOME THERAPEUTICS Reports Third Quarter Fiscal Year 2023 Earnings Results
🌥️Earnings Overview For the third quarter of the Fiscal Year 2023, AXSOME THERAPEUTICS ($NASDAQ:AXSM) reported a total revenue of USD [...]
AXSOME THERAPEUTICS Reports Third Quarter FY2023 Earnings Results on November 6 2023
🌥️Earnings Overview On November 6 2023, AXSOME THERAPEUTICS ($NASDAQ:AXSM) reported their total revenue for the third quarter of FY2023, which [...]
Cantor Fitzgerald Analyzes Axsome Therapeutics,’s FY2024 Earnings
🌥️Trending News Cantor Fitzgerald recently issued an analysis of Axsome Therapeutics ($NASDAQ:AXSM), Inc.'s FY2024 earnings. Axsome Therapeutics, Inc. is a [...]
